Recursion Pharmaceuticals (RXRX) Depreciation and Depletion (2020 - 2024)

Recursion Pharmaceuticals' Depreciation and Depletion history runs 5 years deep, the most recent figure standing at $6.2 million for Q4 2024.

• Quarterly Depreciation and Depletion rose 47.62% year-over-year to $6.2 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $18.3 million (up 14.38% YoY) and the FY2025 annual result came in at $33.7 million, up 84.15% from the prior year.
• Depreciation and Depletion was $6.2 million for Q4 2024 at Recursion Pharmaceuticals, up from $4.0 million in the prior quarter.
• Across five years, Depreciation and Depletion topped out at $6.2 million in Q4 2024 and bottomed at $1.0 million in Q1 2020.
• A 5-year average of $2.9 million and a median of $2.8 million in 2022 frame the typical range for Depreciation and Depletion.
• Annual changes were most pronounced in 2021 — Depreciation and Depletion jumped 140.0% — and 2024, when it slipped 4.76%.
• Recursion Pharmaceuticals' Depreciation and Depletion stood at $1.1 million in 2020, then jumped by 127.27% to $2.5 million in 2021, then rose by 24.0% to $3.1 million in 2022, then surged by 35.48% to $4.2 million in 2023, then jumped by 47.62% to $6.2 million in 2024.
• Business Quant data shows RXRX's Depreciation and Depletion at $6.2 million in Q4 2024, $4.0 million in Q3 2024, and $4.1 million in Q2 2024.